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ABSTRACT
The mechanism of the anti-colorectal cancer (CRC) activity of the omega-3 fatty 
acid eicosapentaenoic acid (EPA) is not understood. We tested the hypothesis that 
EPA reduces expression of chemokine C-C motif ligand 2 (CCL2), a pro-inflammatory 
chemokine with known roles in metastasis.
We measured CCL2 in clinical samples from a randomized trial of EPA in patients 
undergoing liver surgery for CRC liver metastasis (LM) and preclinical models. 
Genome-wide transcriptional profiling of tumors from EPA-treated patients was 
performed.
EPA decreased CCL2 synthesis by CRC cells in a dose-dependent manner. CCL2 
was localized to malignant epithelial cells in human CRCLM. EPA did not reduce CCL2 
content in human or mouse tumors compare to control. However, EPA treatment was 
associated with decreased plasma CCL2 levels compared with controls (P=0.04). 
Reduction in plasma CCL2 following EPA treatment predicted improved disease-free 
survival (HR 0.32; P=0.003). Lack of ‘CCL2 response’ was associated with a specific 
CRCLM gene expression signature.
In conclusion, reduction in plasma CCL2 in patients with CRCLM treated with EPA 
predicts better clinical outcome and a specific tumor gene expression profile. Further 
work is needed to validate CCL2 as a therapeutic response biomarker for omega-3 
fatty acid treatment of CRC patients.
INTRODUCTION
Approximately one third of colorectal cancer (CRC) 
patients develop liver metastasis (LM) within 5 years of 
colorectal surgery, which was originally performed with 
curative intent, and CRCLM is the commonest cause 
of death from CRC [1]. However, only one quarter of 
CRCLM patients are suitable for curative liver resection 
surgery and there is no truly effective medical therapy 
for either prevention or treatment of CRCLM. Therefore, 
there is an unmet clinical need for safe, well-tolerated 
therapy for prevention and treatment of metastatic CRC
There is a large body of human observational 
studies and experimental animal data suggesting that 
the omega-3 polyunsaturated fatty acids (O3FAs) C20:5 
eicosapentaenoic acid (EPA) and C22:6 docosahexaenoic 
acid (DHA) have anti-colorectal cancer (CRC) activity 
[2]. Randomized clinical trial (RCT) data prove that 
EPA 2 g daily, in the free fatty acid (FFA) form, has 
chemopreventative efficacy in familial adenomatous 
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polyposis patients [3]. Moreover, the same formulation 
and dose of EPA has been evaluated in patients undergoing 
liver resection surgery for CRCLM [4]. In this RCT 
(The EMT study; ClinicalTrials.gov NCT01070355), 
patients awaiting liver resection surgery for CRCLM 
were randomized to either EPA-FFA 2 g daily (n=43) or 
placebo (n=45) prior to surgery, for a median duration of 
30 [range 12-65] days and 26 (15-73) days, respectively 
[4]. In this group of patients, EPA treatment was safe and 
well-tolerated [4]. Preliminary data suggested that pre-
operative EPA treatment may improve overall survival 
(OS) and disease-free survival (DFS) [4].
Understanding of the mechanism(s) by which O3FAs 
have anti-CRC activity is limited but several putative 
modes of action are recognized including modulation 
of prostaglandin (PG) metabolism by cyclooxygenase 
(COX)-1 and COX-2, as well as cell surface receptor 
signaling [5]. A central tenet of O3FA mechanism(s) of 
action, pertaining to potential use in several human disease 
states, including cancer and cardiovascular disease, is that 
O3FAs exhibit anti-inflammatory properties [6].
Multiple pro-inflammatory cytokines and 
chemokines link inflammation and carcinogenesis, 
particularly in the gastrointestinal tract [7]. These include 
chemokine C-C motif ligand 2 (CCL2), also known as 
macrophage chemoattractant protein 1 (MCP-1), which 
has been implicated in carcinogenesis and metastasis, 
including in CRC and breast cancer [8, 9]. In clinical 
studies, treatment with O3FAs as fish oil has been 
demonstrated to reduce plasma and adipose tissue levels 
of CCL2 in obese patients with metabolic syndrome [10].
Therefore, we tested the hypothesis that EPA 
decreases plasma and tissue CCL2 levels in pre-clinical 
rodent CRC models and samples from the RCT of EPA in 
CRCLM patients (The EMT study).
RESULTS
EPA treatment is associated with decreased 
plasma CCL2 levels in CRCLM patients 
awaiting liver surgery
As fish oil treatment for 12 weeks has been 
demonstrated to reduce plasma CCL2 levels in obese 
individuals [10], we took advantage of the prospective 
tissue bio-bank obtained from the EMT study [4] in order 
to determine whether a similar phenomenon occurred in 
CRC patients randomized to EPA treatment compared 
with placebo. Pre-treatment plasma CCL2 levels were 
well matched between treatment groups (P=0.66, Mann-
Whitney test). However, reduction in plasma CCL2 after 
EPA treatment was more common (in 19 of 29 [66%] 
individuals) than that at the end of placebo treatment 
(in 10 of 26 [38%] cases; P=0.04; χ2 test; Figure 1A-B). 
Overall, there was an increase in plasma CCL2 level in the 
placebo group at the end of the intervention period, with 
a median increase in CCL2 level of +13.3 pg/ml (range 
-93.1 to +206.2 pg/ml), compared with an overall decrease 
in plasma CCL2 level in those randomized to EPA, who 
exhibited a median change of -12.1 pg/ml (range -119.0 
to +155.1 pg/ml; P<0.05, Mann-Whitney test). These 
results are consistent with negative regulation of CCL2 
production by EPA in patients with metastatic CRC.
EPA decreases CCL2 synthesis by CRC cells in 
vitro
Colorectal cancer liver metastasis tissue analysis 
from the ‘window of opportunity’ EMT study was limited 
to tissue collected after intervention because tumor 
biopsy prior to liver surgery was not possible in patients 
undergoing routine CRCLM surgery [4]. Therefore, we 
were unable to examine whether EPA treatment reduced 
CCL2 content in individual CRCLMs. However, we 
demonstrated that CCL2 is localized predominantly 
to cancer cells in CRCLMs (Figure 1C) rather than in 
stroma-associated cells, as described previously [11]. 
We also measured post-treatment CRCLM CCL2 levels 
in a random subset of CRCLMs from the EMT trial by 
immunoassay. There were a wide range of CCL2 values 
in CRCLM tissues from patients in both placebo and EPA 
arms of the trial (Figure 1D). There was no statistically 
significant difference in tissue CCL2 content between 
CRCLMs from patients treated with EPA before surgery 
(median 151.5 [IQR 25.5-275.0] pg/mg; n=5) compared 
with the placebo arm (median 82.0 [IQR 34.2-231.3] 
pg/mg; n=7). Consistent with similar CCL2 levels in 
CRCLMs, there was no significant difference in the 
density of CD68-positive tumor-associated macrophages 
in CRCLMs from patients treated with placebo (median 
272 cells [IQR 222-375] per hpf; n=24) compared with 
EPA (median 281 cells [IQR 188-362] per hpf; n=28) 
(Figure 1E).
We next performed a screen of three human CRC 
cell lines (SW480, SW620, HCA-7) and observed that 
only HCA-7 human CRC cells generate detectable CCL2 
in conditioned medium (data not shown). There was 
a concentration-dependent relationship between EPA 
exposure and CCL2 release into medium conditioned by 
human HCA-7 CRC cells (Figure 2A), consistent with 
anti-proliferative activity of EPA against this cell line [12]. 
In order to further investigate the relationship between EPA 
treatment and CCL2 levels, we tested the effect of EPA on 
CCL2 production in MC38 cells, which can be used as a 
syngeneic CRC model in C57Bl/6 mice and are widely 
used to model human CRC in vivo based on similarities 
in gene expression profile [13]. Growth of MC38 mouse 
CRC cells was inhibited by EPA in a biphasic manner 
(IC50 values of 10.5±1.0 μM and 154.0±1.1 μM, data not 
shown) and was also associated with a concentration-
dependent decrease in CCL2 synthesis (Figure 2A). The 
impact of EPA treatment on CCL2 production and cell 
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Figure 1: EPA treatment is associated with reduced plasma CCL2 levels in patients with CRCLMs, but no difference in 
CCL2 or macrophage content of CRCLMs. A. The difference in plasma CCL2 levels (pg protein/ml) before and after intervention 
with placebo (n=26) or EPA (n=29), before liver resection surgery. B. Individual paired pre- and post-treatment CCL2 levels (increased 
CCL2 level after intervention, red; decreased CCL2 level after intervention, green. C. Localization of CCL2 in human CRCLMs by 
immunofluorescence. Images were obtained from patient samples with tumor tissue CCL2 levels of 225 pg/mg (i) and 34 pg/mg (ii) and 
plasma CCL2 levels of 135.4 pg/ml (i) and 150.8 pg/ml (ii). The fluorescence pattern indicates predominant localization of CCL2 (green) 
in malignant epithelial cells, (iii) negative control with omission of the primary antibody. Tumor epithelium is delineated by white lines. 
Stromal cells were consistently negative. D. Tissue CCL2 levels in CRCLMs from patients allocated to either placebo (n=7) or EPA (n=5). 
The bar indicates the median value for each group. E. CD68-positive tumor-associated macrophage content of CRCLMs from patients 
allocated to either placebo (n=24) or EPA (n=28). Three tumors were not analyzed as there was insufficient tissue for histological analysis. 
The bar indicates the median value.
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Figure 2: EPA inhibits CCL2 secretion and CCR2 expression in CRC cells in a concentration-dependent manner. 
A. Mouse MC38 ( ) and human HCA-7 ( ) CRC cells were exposed to increasing concentrations of EPA for 24 hrs. Columns and bars 
represent the mean and standard deviation (n=3). B. CCR2 immunofluorescence intensity. Columns and bars represent the mean value 
and standard deviation for each condition. C. CCR2 protein localization in mouse MC38 CRC cells in the presence or absence of EPA for 
24 hrs. D. Effect of EP4 receptor agonists (PGE2, PGE1-alcohol), EP4 receptor antagonist ONO-AE3-208, and the MAP Kinase inhibitor 
PD98059 on CCL2 production by MC38 cells. Columns and bars represent the mean and standard deviation (n=3). The Mann-Whitney 
test was used to test statistical significance.
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proliferation was greater in MC38 cells than in the HCA-
7 cells, which is consistent with the fact that HCA-7 cells 
were less sensitive to EPA than MC38 cells (HCA-7 IC50 
154.0±1.1 μM, data not shown). We demonstrated that 
EPA treatment also reduced the CCL2 receptor CCR2 
expression in MC38 mouse CRC cells (Figure 2B–2C). 
Immunofluorescence microscopy revealed that exposure 
to 100 μM EPA for 24 hours decreased CCR2 expression 
in MC38 cells to 36±4% of the level in untreated cells 
(Figure 2C).
Both the CCL2-expressing CRC cell lines also 
exhibit constitutive COX-2 expression and PGE2 synthesis 
[12,14]. Moreover, EPA treatment inhibits PGE2 synthesis 
and downstream EP4 receptor activation in CRC cells 
[12]. Therefore, we investigated whether EPA decreased 
CCL2 production in a PGE2-EP4 receptor-dependent 
manner in MC38 cells. Neither PGE2, nor the selective EP4 
receptor agonist PGE1-alcohol, rescued down-regulation 
of CCL2 by EPA. In addition, neither the EP4 receptor 
antagonist ONO-AE3-208, nor inhibition of MAP kinase 
by PD98059, decreased CCL2 synthesis (Figure 2D). 
Therefore, EPA abrogates CCL2 synthesis and release in a 
PGE2-EP4 receptor-independent manner in MC38 mouse 
CRC cells.
EPA treatment is not associated with reduced 
tumor CCL2 content in vivo
The fact that MC38 mouse CRC cells grow readily 
as discrete tumors in syngeneic C57BL/6 mice allowed us 
to determine whether EPA treatment was associated with 
lower CCL2 expression in vivo, albeit with the similar 
proviso to human CRCLMs that paired pre- and post-
treatment levels from the same tumor were unavailable. 
Animals with subcutaneous MC38 cell tumors were fed a 
control or 5% (w/w) EPA-containing diet. In keeping with 
the anti-neoplastic activity of EPA against MC38 mouse 
CRC cells in vitro, there was a significant reduction in 
MC38 cell tumor weight in mice provided with the 5% 
EPA-containing diet (median tumor wet weight 0.18 g 
[range 0.07-0.39 g]) compared to animals fed the control 
diet (0.26 g [0.06-1.19 g]; P=0.04; Figure 3A).
Control MC38 tumors exhibited a wide range of 
intra-tumoral CCL2 levels (median 142.0 [range 21.1-
279.8] pg/mg). The levels measured in tumors from 
mice fed a 5% EPA-containing diet were lower (median 
106.8 [0.3-220.8] pg/mg) but the difference was not 
statistically significant (Figure 3B), consistent with the 
human CRCLM data, which was also limited to post-
treatment analysis. There was no significant difference 
in the percentage of F4/80-positive tumor-associated 
macrophages relative to total cell population analyzed 
in tumors from the two treatment groups (Figure 3C). 
There was also no significant difference in tumor-
associated macrophage M1-M2 phenotype polarization, 
as determined by CD11c and CD206 phenotyping, 
with a dominant CD11c+ CD206- M1 F4/80+ CD11b+ 
macrophage population observed in both treatment groups 
(Figure 3D). These data suggest that anti-tumor activity 
of EPA in the MC38 mouse CRC model is most likely 
independent of tumor-associated macrophage recruitment 
and phenotype.
In summary, we were unable to link longitudinal 
reduction in plasma CCL2 following EPA treatment in 
humans with any significant difference in intra-tumoral 
CCL2 content measured after EPA treatment in either 
human or mouse tumors.
EPA treatment does not reduce ex vivo CCL2 
synthesis by human PBMCs
CCL2 expression has been shown to be increased in 
activated human PBMCs from non-small cell lung cancer 
patients [15]. Therefore, we measured ex vivo CCL2 
synthesis by LPS-treated PBMCs, which were obtained 
from patients in the EMT study at the same time as plasma, 
before and after treatment with either EPA or placebo. 
CCL2 protein levels in conditioned medium, normalized 
for PBMC number, were similar before treatment with a 
median CCL2 protein level of 17.9 (range 10.9-97.8) ng/
ml in the control group and 28.8 (range 5.0-200.0) ng/ml 
in the EPA-treated group. Comparison of ex vivo CCL2 
production by PBMCs before and after EPA or placebo did 
not reveal any significant difference between the groups 
(median differential [post- minus pre-treatment] CCL2 5.0 
[range -39.9 to +94.8] ng/ml in those allocated placebo 
compared with 10.1 [range -462.3 to +155.3] ng/ml in 
the EPA treatment group; p=0.41; Figure 4). Therefore, 
alteration of CCL2 production by circulating monocytes 
is unlikely to explain the reduction in plasma CCL2 levels 
observed in patients treated with EPA.
Reduction in plasma CCL2 levels after EPA 
treatment discriminates between different gene 
expression profiles in CRCLMs and predicts 
post-operative outcomes
Next, we sought evidence of differences in CRCLM 
gene expression in EPA-treated patients who either 
demonstrated a reduction in plasma CCL2 levels or 
showed either no change or an increase in CCL2 plasma 
levels. Using a whole genome expression array, we 
identified 614 genes, which were differentially expressed 
(P<0.05) in tumor cell from patients with decreased CCL2 
plasma levels compared to patients with no change or an 
increase in CCL2 plasma levels. Unsupervised hierarchical 
clustering of the differentially expressed genes clearly 
segregated CRCLMs according to the change in plasma 
CCL2 level after EPA treatment (Figure 5A).
MetaCore™ was used to for enrichment analysis 
(Supplementary Table 2). Tumors from patients who 
demonstrated no change or an increase in plasma CCL2 
level following EPA treatment displayed enrichment of 
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Figure 3: Effect of EPA on CCL2 level and tumor-associated macrophage profile in mouse MC38 CRC cell tumors in 
vivo. A. Subcutaneous MC38 CRC cell tumor weight at sacrifice in animals provided with control or 5% EPA-containing diet (both groups 
n=16). B. CCL2 protein levels in MC38 CRC cell tumors. C. F4/80-positive macrophage content of MC38 CRC cell tumors. D. F4/80+ 
CD11b+ macrophage polarization analyzed by CD206 and CD11c expression.
Figure 4: Ex vivo CCL2 production by LPS-stimulated PBMCs from patients treated with either placebo or EPA. 
Bars represent the difference between post-treatment and pre-treatment levels in individual patients (placebo, n=26; EPA, n=29). Negative 
values indicate reduction in CCL2 level in PBMC-conditioned medium at the end of the treatment period. Conversely, positive values 
indicate an increase in CCL2 level in PBMC-conditioned medium after intervention.
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Figure 5: Differential gene expression in CRCLMs and clinical outcomes of EPA-treated CRCLM patients. A. Heat 
map of unsupervised clustering of gene expression profiles of CRCLMs from 15 patients who received EPA, of which 4 demonstrated an 
increase in plasma CCL2 at the end of EPA treatment (red) and 11 demonstrated a decrease in plasma CCL2 at the end of the intervention 
period (green) compared with pretreatment values. The color scale indicates the range of z-score values for each sample. B. Kaplan-Meier 
curves for DFS of EPA-treated patients who either had a decrease (green line) or increase (red line) in plasma CCL2 after EPA treatment 
prior to CRCLM surgery. P=0.003 log rank test.
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pathways linked to chemokine production and glucose 
metabolism, as well as down-regulation of transcription 
control pathways and apoptosis signaling.
A marked difference in global gene expression 
between CRCLMs from individuals who had either a 
decrease or increase in plasma CCL2 level following EPA 
treatment prompted analysis of post-trial clinical outcomes 
in these two groups.
There was a statistically significant difference 
in DFS after CRCLM surgery between patients whose 
plasma CCL2 level increased during treatment compared 
with individuals in whom the plasma CCL2 level 
decreased following treatment (Figure 5B). EPA-treated 
patients whose plasma CCL2 level decreased following 
EPA treatment had a significantly better DFS (median 23.5 
months), compared with individuals in whom the plasma 
CCL2 level increased during EPA treatment (median 6.1 
months), with a HR of 0.32 (95% confidence interval 0.05-
0.51; P=0.003). By contrast, the relationship between the 
change in plasma CCL2 level and DFS was the opposite in 
the placebo arm (HR 2.09 [95% confidence interval 1.08-
6.76] with a median DFS of 23.6 months and 13.8 months 
for patients with increased and decreased plasma CCL2 
levels after placebo treatment, respectively (P=0.05). 
By contrast, there was no correlation between the pre-
treatment plasma CCL2 level at randomization and DFS 
in either EMT study treatment group (data not shown).
DISCUSSION
We conclude that treatment with the O3FA EPA 
is associated with an overall reduction in plasma CCL2 
concentration in patients with CRCLM. Moreover, an 
increase in plasma CCL2 during EPA treatment predicts 
worse clinical outcome after CRCLM surgery and selects 
for a distinct CRCLM gene expression profile.
Our data are consistent with other studies, which 
have reported that plasma CCL2 levels in CRC patients 
are in the pg/ml range [16] and that O3FA treatment 
is associated with a reduction in circulating CCL2 
concentration [10]. However, a shorter-term (8 weeks) 
study with daily dosing of 3.6 g mixed O3FAs did not 
detect a change in plasma CCL2 levels [17]. Potential 
confounders of the plasma CCL2 level in CRC patients 
include body weight and physical activity [18,19].
Tissue CCL2 content predicts poor clinical 
outcome in colorectal cancer and breast cancer [20–22]. 
Specifically, CCL2 immunoreactivity in primary CRC 
tumors, as measured by immunohistochemistry, predicts 
future liver metastasis [20] and CCL2 staining in CRCLMs 
predicts CRCLM recurrence and overall survival after 
CRCLM resection surgery [11]. However, we were unable 
to obtain specific, reproducible immunostaining of fixed 
CRCLM tissue using any commercially available anti-
CCL2 antibody, with which to explore whether CRCLM 
content predicts survival. Circulating CCL2 levels in CRC 
patients have only been described once [23]. Szczepanik 
and colleagues have reported that the pre-operative serum 
CCL2 level is a prognostic factor in patients undergoing 
primary CRC resection [23].
We suggest that EPA treatment most likely reduces 
CRC cell CCL2 production in a PGE2-independent manner 
based on our in vitro data and those of others [24]. We 
also found a concomitant reduction of the CCL2 receptor 
CCR2 expression in CRC cells in vitro. This is in keeping 
with a study by Fang et al., which described a correlation 
between CCL2 and CCR2 expression levels in breast 
cancer [25]. We hypothesize that our inability to detect a 
reduction in tumor CCL2 content in vivo is due to the lack 
of paired human or mouse tumor tissue samples before and 
after EPA treatment combined with tumor heterogeneity of 
CCL2 expression.
It remains unclear what the cellular source of plasma 
CCL2 is. It is established that human colorectal adenomas 
and CRCs have elevated levels of CCL2 protein [11,24], 
which is localized to cancer cells, consistent with the 
production of CCL2 by human CRC cells in vitro [24]. 
We established that human CRCLMs contain CCL2 by 
immunoassay but were unable to detect any correlation 
between tissue CCL2 protein concentration and the post-
treatment plasma CCL2 level in individuals from either the 
placebo or EPA arms of the EMT trial (data not shown). 
Our ex vivo PBMC culture experiments suggest that 
circulating monocytes are not the predominant source of 
CCL2 in plasma relevant to its role as a putative predictive 
biomarker, on the basis that EPA did not significantly alter 
ex vivo PBMC CCL2 production.
Surprisingly, given the role of CCL2 in tumor-
associated macrophage chemotaxis [8] and association 
between CCL2 content and macrophage infiltrate in 
colonic tumors [22, 24, 26], we did not detect any effect 
of EPA on macrophage content of either human or 
mouse tumors, or any significant change in macrophage 
polarization in MC38 CRC cell tumors from C57BL/6 
mice exposed to EPA in the diet. Despite this, it is clear 
that a reduction in plasma CCL2 associated with EPA 
treatment is linked to a marked difference in tumor 
biology evidenced by the differential gene expression 
between tumors from patients who did or did not exhibit 
a ‘CCL2 response’.
Importantly, the plasma ‘CCL2 response’ predicted 
clinical outcome in patients who received EPA treatment 
prior to CRCLM surgery. The predictive value of the 
plasma ‘CCL2 response’ to EPA treatment should be 
tested prospectively during planned phase III evaluation 
of adjuvant EPA treatment in patients undergoing CRCLM 
surgery. The interaction between CCL2 expression/activity 
and CRC recurrence requires further investigation in light 
of the opposite relationship between the change in plasma 
CCL2 level and CRC recurrence in the absence of EPA 
treatment, although the relatively small effect size could 
imply a chance finding. The possibility of combining 
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EPA treatment with therapies targeting the CCL2/CCR2 
signaling pathway should be explored. Several groups 
have recently reported that blocking CCL2 signaling may 
be effective in breast cancer and metastatic breast cancer 
patients [27–28]. However a recent report suggests that 
anti-CCL2 therapy may result in a surge in CCL2 levels 
and subsequent tumor growth after the treatment phase has 
ended [29]. It may be that targeting the CCR2 receptor 
will be more efficacious. A phase I trial is currently 
underway to assess to safety and tolerability of such an 
approach in pancreatic cancer patients (clinicaltrials.gov 
NCT02345408).
MATERIALS AND METHODS
Clinical samples
Blood samples were obtained from participants of 
the EMT study at randomization and on the day before 
surgery, from which peripheral blood mononuclear cells 
(PBMCs) and plasma samples were prepared [4]. We 
excluded patients with high dietary fish intake (> 2 oily 
fish portions per week) and/or previous users of fish oil 
supplements from the current analysis, providing paired 
samples from 55 patients (26 placebo, 29 EPA-FFA).
PBMCs were isolated from blood using Vacutainer 
CPT™ tubes (BD Medical, NJ, USA) and viable cells 
counted using a haemocytometer in the presence of 
0.04% (v/v) trypan blue (Sigma-Aldrich, UK). Cells 
were cultured in RPMI 1640 medium (Invitrogen, UK), 
containing Glutamax® supplemented with 10% (v/v) heat-
inactivated foetal bovine serum (FBS, Sigma-Aldrich, 
UK) in the presence of 1 μg/ml lipopolysaccharide (E. 
coli 026:B6; Sigma-Aldrich), for 24 hours before PBMC-
conditioned medium was collected.
All samples were stored in a Human Tissue Act-
approved tissue bank at -80oC. Fresh frozen tumor 
tissue was defrosted on ice and placed in 1 ml of ice-
cold phosphate-buffered saline (PBS) supplemented 
with protease inhibitor cocktail (both Sigma, UK) and 
homogenized using a mechanical blender. Homogenates 
were centrifuged for 3 min at 9000 g to remove debris. 
Protein concentration was measured using a DC protein 
assay (Bio-Rad Laboratories Ltd., Hemel Hempstead, 
UK). CCL2 was measured using the R&D Systems 
(Abingdon, UK) human CCL2 immunoassay.
Immunohistochemistry for CD68 was performed 
using mouse monoclonal anti-human CD68 (KP1 clone) 
antibody (Dako UK Ltd., Ely, UK). Immunoreactivity 
was visualized using a DAKO EnVision™+ kit. CD68 
scoring was performed by an operator blinded to sample 
allocation. Five high power field (hpf, x 200) images were 
acquired at random. Digital images were prepared using 
Leica LAS-AF Lite Software (Leica Microsystems [UK], 
Milton Keynes), and were further processed using Adobe 
Photoshop CS5.1 (Adobe Systems Inc., San Jose, CA). 
The mean number of stained positive cells per hpf was 
quantified using ImageJ software (National Institutes of 
Health, Bethesda, MD).
Immunocytochemistry for CCL2 was performed on 
OCT-embedded CRCLM tissue. Sections were thawed for 
20 min at room temperature then hydrated in Tris-buffered 
saline (TBS) for 20 min. After blocking with Invitrogen 
antibody diluent (Invitrogen), sections were stained with 
mouse monoclonal anti-human CCL2 antibody (Millipore 
MABN712) followed by the AlexaFluor® 488-goat anti-
mouse IgG antibody (Invitrogen). Sections were mounted 
using DAPI-Prolong Gold (Invitrogen) and visualized 
using a Zeiss AxioImager.Z1 fluorescence microscope.
In vitro studies
EPA-FFA was a gift from SLA Pharma AG (Watford, 
UK), and is referred to henceforth as EPA. Use of EPA in 
in vitro experiments has been described previously [12]. 
PGE2, PGE1 alcohol and ONO-AE3-208 were obtained 
from Cayman (USA). PD98058 was obtained from 
Sigma (UK).
MC38 mouse CRC cells were a gift from D. 
Beauchamp (Vanderbilt University, TN, USA). HCA-7 
human CRC cells were obtained from Sigma-Aldrich and 
RAW264.7 mouse macrophages were obtained from the 
ATCC (www.atcc.org). HCA-7 cells were authenticated by 
STR profiling. Cells were cultured in RPMI 1640 medium 
containing Glutamax® supplemented with 10% (v/v) FBS, 
at 37°C in a humidified atmosphere containing 5% CO2.
Cell chemosensitivity to EPA was determined using 
the MTT assay [30]. Briefly, cells were seeded in 96-well 
plates and incubated overnight at 37oC. The following 
day, the medium was removed and replaced with fresh 
medium containing EPA for 96 hrs at 37oC. Cell survival 
was determined using the MTT assay. IC50 values were 
calculated using Prism6™ software and are expressed 
as the mean ± standard deviation of three independent 
experiments.
Culture medium was conditioned by 1x105 cells 
in 6-well plate wells at 37oC for 24 hrs, in the presence 
or absence of 50-200μM EPA, EP receptor agonists/
antagonist and 30μM PD98058. CCL2 levels were 
measured using a mouse or human CCL2 immunoassay 
(both R&D Systems).
Immunofluorescence for CCR2
Cells were seeded onto glass coverslips in 6-well 
plates and incubated at 37oC for 24 hrs. Cells were treated 
with 2 ml of fresh medium containing ethanol carrier 
or varying concentrations of EPA for 24 hrs. Following 
methanol fixation, CCR2 detection was performed using 
rabbit anti-mouse CCR2 antibody (GeneTex GTX61660) 
followed by AlexaFluor® 594 donkey anti-rabbit IgG 
(Invitrogen). Coverslips were mounted on slides using 
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DAPI-Prolong Gold (Invitrogen). Fluorescence intensity 
was measured using ImageJ software. Integrated intensity 
was calculated as the mean fluorescence intensity from 5 
independent fields minus the mean background intensity 
from 5 areas with no cellular fluorescence. Data are 
expressed as the mean ± standard deviation from three 
independent experiments
In vivo studies
C57BL/6 mice were housed in a specific pathogen-
free environment. All experiments were undertaken with 
UK Home Office approval. Female, 8 week-old C57BL/6 
mice were administered isocaloric diets (n=16 per group) 
ad libitum for 14 days based on a modified AIN-93G diet 
base, in which 7% soybean oil was replaced by either 5% 
(w/w) EPA and corn oil, or corn oil alone (Supplementary 
Table 1). Fresh diet was manufactured by IPS Ltd. 
(London, UK) every 8 days and delivered within 48 hrs 
in vacuum-packed 100 g foil bags in order to minimize 
oxidation [14]. Uneaten food was replaced every day with 
fresh diet from a previously unopened bag.
On day 15, 1 x 106 MC38 mouse CRC cells in 100 
μl sterile PBS were injected subcutaneously on the flank. 
Animals continued on the same diet and were weighed 
daily for a further 14 days until sacrifice. Immediately 
after sacrifice, tumor weight and volume were measured 
blind to diet allocation. Each tumor sample was fixed in 
4% (w/v) paraformaldehyde in PBS overnight, prior to 
embedding in paraffin, and was snap-frozen in liquid N2 
before storage at -80oC.
Single tumor cell suspensions were prepared using 
1 mg/ml type IV collagenase and 40 μg/ml DNase (Life 
Technologies, Paisley, UK) in HEPES-buffered saline 
solution (HBSS) at 37oC for 20 min. All suspensions were 
passed through a 4 μm cell strainer and washed thoroughly 
before re-suspension in PBS with 0.5% (w/v) BSA for 
antibody staining. Cell suspensions were stained with 
CD45-Peridinin Chlorophyll Protein Complex (PerCP) 
(30F11), CD11b-R-phycoerythrin (PE) (M1/70), CD11c-
Brilliant Violet 421 (BV421) (N418) (BD Biosciences, 
Oxford, UK), F4/80-Fluorescein isothiocyanate (FITC) 
(Cl:A3-1) (AB Serotec, Kidlington, UK), CD206-
Allophycocyanin (APC) (clone 15-2) (Biolegend, 
London, UK). Surface antigen expression was assessed 
by flow cytometry using a LSRII flow cytometer (BD 
Biosciences).
Whole genome expression analysis
Formalin-fixed paraffin-embedded CRCLM blocks 
were sampled using a TMA needle as previously described 
[31]. Total RNA was extracted using the AllPrep DNA/
RNA FFPE kit (Qiagen Ltd., Manchester, UK). Fifteen 
of twenty CRCLM blocks yielded total RNA of sufficient 
quality (RNA concentration >20 ng/μl and A260/A280 >1.95) 
for microarray analysis. Two samples were run with 
technical duplicates, which showed good reproducibility 
for hybridization, normalization of the data and clustering 
(data not shown). Whole genome expression profiles 
were generated using the Affymetrix GeneChip® Human 
Transcriptome Array 2.0 (>6 million probes). Gene 
expression data were pre-processed using proprietary 
Affymetrix® Expression Console™ v1.3 software. The 
raw gene expression data (CEL files) were processed using 
the Robust Multichip Analysis (RMA) algorithm [32] 
which fits a linear model at probe level allowing the effect 
of differences in probe-specific affinity to be minimized 
and providing increased sensitivity to detect small 
changes between experimental and control samples. The 
RMA algorithm performs global background adjustment 
of the data from each chip prior to inter-array quantile 
normalization. Probe level expression values were then 
summarized to give gene-level expression values. Raw 
CEL files and processed RMA files are available in the 
GEO repository under the series set GSE79266.
Differential gene expression analysis was performed 
in R [33]. The Bioconductor genefilter package was used 
to perform a two-sided, two-class t-test for each gene 
against experimental status (increased or decreased CCL2 
plasma level) [34]. Genes with an equivalent fold change 
of ±1.2 (the median fold-change value) and a p-value of 
<0.05 were determined to be differentially expressed. 
Unsupervised hierarchical clustering of differentially 
expressed genes was performed using the pheatmap 
package [35].
MetaCore™ v6.21 (build 66768) software 
(Thomson Reuters, https://portal.genego.com.) was used 
to identify which pathways were enriched from the list of 
differentially expressed genes.
Statistical analysis
The Mann-Whitney test was used to analyze data 
unless specified otherwise above. The log-rank test was 
used to assess the significance of the survival analysis 
exploring the relationship between changes in CCL2 
levels and clinical outcomes.
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